|
70
|
243
|
5fghF |
Yeast 20s proteasome beta5-k33a mutant (propeptide expressed in trans) in complex with mg132 |
|
57
|
204
|
5fhsI |
Yeast 20s proteasome beta5-k33a mutant (propeptide expressed in trans) in complex with carfilzomib |
|
61
|
222
|
5fgeL |
Yeast 20s proteasome beta5-h(-2)t-t1a double mutant in complex with carfilzomib |
|
68
|
240
|
5fhsC |
Yeast 20s proteasome beta5-k33a mutant (propeptide expressed in trans) in complex with carfilzomib |
|
67
|
240
|
5fgiC |
Yeast 20s proteasome beta1-t1a beta2-t1a double mutant in complex with carfilzomib |
|
39
|
205
|
5fmgM |
Structure and function based design of plasmodium-selective proteasome inhibitors |
|
61
|
195
|
5fg9J |
Yeast 20s proteasome beta2-t(-2)v mutant |
|
68
|
243
|
5fgaF |
Yeast 20s proteasome beta5-k33a mutant (propeptide expressed in trans) |
|
56
|
204
|
5fghI |
Yeast 20s proteasome beta5-k33a mutant (propeptide expressed in trans) in complex with mg132 |
|
62
|
241
|
5fhsG |
Yeast 20s proteasome beta5-k33a mutant (propeptide expressed in trans) in complex with carfilzomib |
|
39
|
194
|
5fmgL |
Structure and function based design of plasmodium-selective proteasome inhibitors |
|
68
|
233
|
5fgaM |
Yeast 20s proteasome beta5-k33a mutant (propeptide expressed in trans) |
|
67
|
212
|
5fghK |
Yeast 20s proteasome beta5-k33a mutant (propeptide expressed in trans) in complex with mg132 |
|
58
|
222
|
5fgfH |
Yeast 20s proteasome beta5-h(-2)a-t1a-k81r triple mutant in complex with carfilzomib |
|
65
|
242
|
5fgeD |
Yeast 20s proteasome beta5-h(-2)t-t1a double mutant in complex with carfilzomib |
|
60
|
196
|
5fg7N |
Yeast 20s proteasome beta2-t1a mutant |
|
63
|
241
|
5fgeG |
Yeast 20s proteasome beta5-h(-2)t-t1a double mutant in complex with carfilzomib |
|
68
|
232
|
5fgiM |
Yeast 20s proteasome beta1-t1a beta2-t1a double mutant in complex with carfilzomib |
|
61
|
222
|
5fg7L |
Yeast 20s proteasome beta2-t1a mutant |
|
69
|
240
|
5fggC |
Yeast 20s proteasome beta5-l(-49s)_d17n double mutant in complex with carfilzomib |
|
60
|
222
|
5fggL |
Yeast 20s proteasome beta5-l(-49s)_d17n double mutant in complex with carfilzomib |
|
67
|
242
|
5fg9D |
Yeast 20s proteasome beta2-t(-2)v mutant |
|
60
|
196
|
5fgdN |
Yeast 20s proteasome beta5-h(-2)l-t1a double mutant in complex with carfilzomib |
|
60
|
196
|
5fgeN |
Yeast 20s proteasome beta5-h(-2)t-t1a double mutant in complex with carfilzomib |
|
62
|
195
|
5fggJ |
Yeast 20s proteasome beta5-l(-49s)_d17n double mutant in complex with carfilzomib |
|
34
|
247
|
5fmgH |
Structure and function based design of plasmodium-selective proteasome inhibitors |
|
69
|
240
|
5fgeC |
Yeast 20s proteasome beta5-h(-2)t-t1a double mutant in complex with carfilzomib |
|
59
|
222
|
5fghL |
Yeast 20s proteasome beta5-k33a mutant (propeptide expressed in trans) in complex with mg132 |
|
62
|
222
|
5fgaL |
Yeast 20s proteasome beta5-k33a mutant (propeptide expressed in trans) |
|
59
|
222
|
5fgiL |
Yeast 20s proteasome beta1-t1a beta2-t1a double mutant in complex with carfilzomib |
|
62
|
228
|
5fg7H |
Yeast 20s proteasome beta2-t1a mutant |
|
71
|
233
|
5fg7M |
Yeast 20s proteasome beta2-t1a mutant |
|
59
|
196
|
5fghN |
Yeast 20s proteasome beta5-k33a mutant (propeptide expressed in trans) in complex with mg132 |
|
61
|
195
|
5fhsJ |
Yeast 20s proteasome beta5-k33a mutant (propeptide expressed in trans) in complex with carfilzomib |
|
57
|
226
|
5fgaH |
Yeast 20s proteasome beta5-k33a mutant (propeptide expressed in trans) |
|
67
|
233
|
5fghM |
Yeast 20s proteasome beta5-k33a mutant (propeptide expressed in trans) in complex with mg132 |
|
68
|
244
|
5fgdB |
Yeast 20s proteasome beta5-h(-2)l-t1a double mutant in complex with carfilzomib |
|
62
|
241
|
5fg9G |
Yeast 20s proteasome beta2-t(-2)v mutant |
|
69
|
250
|
5fhsA |
Yeast 20s proteasome beta5-k33a mutant (propeptide expressed in trans) in complex with carfilzomib |
|
72
|
240
|
5fg9C |
Yeast 20s proteasome beta2-t(-2)v mutant |
|
72
|
214
|
5fgfK |
Yeast 20s proteasome beta5-h(-2)a-t1a-k81r triple mutant in complex with carfilzomib |
|
40
|
194
|
5fmgK |
Structure and function based design of plasmodium-selective proteasome inhibitors |
|
64
|
231
|
5fg9E |
Yeast 20s proteasome beta2-t(-2)v mutant |
|
62
|
241
|
5fgiG |
Yeast 20s proteasome beta1-t1a beta2-t1a double mutant in complex with carfilzomib |
|
50
|
232
|
5fmgC |
Structure and function based design of plasmodium-selective proteasome inhibitors |
|
70
|
212
|
5fg9K |
Yeast 20s proteasome beta2-t(-2)v mutant |
|
58
|
204
|
5fgaI |
Yeast 20s proteasome beta5-k33a mutant (propeptide expressed in trans) |
|
63
|
241
|
5fgaG |
Yeast 20s proteasome beta5-k33a mutant (propeptide expressed in trans) |
|
64
|
233
|
5fgdM |
Yeast 20s proteasome beta5-h(-2)l-t1a double mutant in complex with carfilzomib |
|
39
|
247
|
5fmgA |
Structure and function based design of plasmodium-selective proteasome inhibitors |
